论文部分内容阅读
目的探讨晚期消化道肿瘤应用替吉奥与氟尿嘧啶治疗的临床预后对比。方法本次共选择100例晚期消化道肿瘤患者作研究对象,均为本院2012年10月~2013年10月收治,采用数字表抽取法随机划分,就替吉奥治疗(A组,n=50)与氟尿嘧啶治疗(B组,n=50)效果进行比较。结果两组6、12、18、24个月总生存率及无病生存率差异无统计学意义(P>0.05)。A组中性粒细胞减少率明显少于B组(P<0.05)。结论晚期消化道肿瘤患者采用替吉奥治疗,可避免中性粒减少等不良反应的发生,虽不具延长生存期疗效,但使患者生存质量明显改善,具较高应用价值。
Objective To investigate the clinical prognosis of patients with advanced gastrointestinal cancer treated with tegaserod and fluorouracil. Methods A total of 100 cases of patients with advanced gastrointestinal cancer were selected as study subjects. All patients were admitted to our hospital from October 2012 to October 2013. The patients were randomly divided into three groups according to Gio (A group, n = 50) compared with fluorouracil (group B, n = 50). Results There was no significant difference in the overall survival rate and disease-free survival rate between the two groups at 6, 12, 18, 24 months (P> 0.05). A group of neutropenia was significantly less than the B group (P <0.05). Conclusion The treatment of patients with advanced gastrointestinal cancer with tigao avoids the occurrence of adverse reactions such as neutropenia. Although it does not prolong the curative effect of survival, it can improve the quality of life of patients and has higher value.